Clinical Trials
11 trialsNCT07612137 2026-05-28
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Not yet recruiting
NCT07603791 2026-05-22
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 2 Not yet recruiting
NCT07376382 2026-05-13
SYNSTAR-02
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07486648 2026-03-24
Precision
Shanxi Province Cancer Hospital
Phase 1/2 Not yet recruiting
NCT07485452 2026-03-20
OSIBBBOOST
Maastricht University Medical Center
Phase 2 Not yet recruiting
NCT07361705 2026-01-23
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 1 Not yet recruiting
NCT07153055 2025-12-18
LOTS
Indiana University
Phase 1/2 Not yet recruiting
NCT07285148 2025-12-16
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2 Not yet recruiting
NCT07256509 2025-12-05
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2 Not yet recruiting
NCT07177092 2025-09-16
SURGAN-TKI
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT07038460 2025-06-26
NEO-LISI
Guangdong Provincial People's Hospital
Phase 2 Not yet recruiting